Quantum Genomics SA is a France-based biopharmaceutical company. The Company provides biotechnological and medical research. Its main activity is research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors). Quantum Genomics SA's activities are oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The Company also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The Company is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.